Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?
- Vadim TchaikovskiAffiliated withHaemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham
- , Gregory Y. H. LipAffiliated withHaemostasis, Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The possibility of carcinogenic side effects of antihypertensive therapies due to their chronic administration has been raised multiple times in the past. Recently, the issue has again drawn attention, this time in relation to angiotensin receptor blockers (ARBs). This, among others, caused both American and European drug regulation authorities to review the underlying evidence concerning the relationship between this class of medications and potential adverse carcinogenic outcome. A plethora of both basic science and preclinical evidence has been generated, and three meta-analyses and one nationwide cohort have focused on this specific question. The current review aims to summarize the contemporary multidisciplinary evidence on whether ARBs may be associated with an increased risk of tumorigenesis.
KeywordsAngiotensin receptor blockers Hypertension Blood pressure Cancer Tumorigenesis Carcinogenic Antihypertensive therapy Angiotensin Cardiovascular disease Cardiovascular risk Angiotensin-converting enzyme ACE ACE inhibitor Renin-angiotensin system AT1R AT2R Breast cancer Lung cancer
- Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?
Current Hypertension Reports
Volume 14, Issue 3 , pp 183-192
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Angiotensin receptor blockers
- Blood pressure
- Antihypertensive therapy
- Cardiovascular disease
- Cardiovascular risk
- Angiotensin-converting enzyme
- ACE inhibitor
- Renin-angiotensin system
- Breast cancer
- Lung cancer
- Industry Sectors